Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1366-1372

  Li, Ying ^a,b   Feng, Lili ^a   Jiang, Wen ^c   Shan, Ningning ^a   Wang, Xin ^a,b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Anti leukemia; Arsenic trioxide; Artesunate

Indexed keywords

ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; ARTESUNATE; FAS ANTIGEN; FAS LIGAND; PROTEIN C FOS; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; ORGANOARSENIC DERIVATIVE; OXIDE;

ACUTE LEUKEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ART THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL GROWTH; CELL ORGANELLE; CELL PROLIFERATION; CELL STRUCTURE; CELL SURFACE; CELL SWELLING; CELL VOLUME; CHROMATIN CONDENSATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SAFETY; DRUG TOXICITY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPE; HUMAN; HUMAN CELL; IN VITRO STUDY; K562 CELL LINE; LEUKEMIA; LEUKEMIA CELL LINE; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; TRANSMISSION ELECTRON MICROSCOPY; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; TUMOR CELL LINE; U937 CELL LINE;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; ARTEMISININS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FAS LIGAND PROTEIN; HUMANS; K562 CELLS; LEUKEMIA; OXIDES; PROTO-ONCOGENE PROTEINS C-FOS; U937 CELLS;

EID: 84901330821     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.829573     Document Type: Article

References (21)

1. Krishna S, Bustamante L, Haynes RK, et al. HM. Artemisinins: Their growing importance in medicine. Trends Pharmacol Sci 2008; 29 : 520-527
2. Zeng QP, Zhang PZ. Artesunate mitigates proliferation of tumor cells by alkylating heme-harboring nitric oxide synthase. Nitric Oxide 2011; 24: 110-112
3. Steinbruck L, Pereira G, Efferth T. Effects of artesunate on cytokinesis and G/M cell cycle progression of tumour cells and budding yeast. Cancer Genomics Proteomics 2010; 7: 337-346
4. Zhou H J, Wang W Q, Wu G D, et al. Artesunate inhibits angiogenesis and downregulates vascular endothelial growThfactor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 2007; 47 : 131-138
5. Rasheed SA, EfferThT, Asangani I A, et al. First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 2010; 127: 1475-1485
6. Du JH, Zhang HD, Ma ZJ, et al. Artesunate induces oncosis-like cell deaThin vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 2010; 65: 895-902
7. Li S, Xue F, Cheng Z, et al. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through aff ecting NFkappaB p65. Int J Hematol 2009; 90: 513-521
8. Li H M, Long Y, Qing C, et al. Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis. Oncol Res 2011; 19: 149-163
9. Griffin RJ, Williams BW, Koonce NA, et al. Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors. J Oncol 2012; 2012: 934918
10. Singh NP, Lai HC, Park JS, et al. Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. Anticancer Res 2011 ; 31: 4111-4114
11. Buommino E, Baroni A, Canozo N, et al. Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs 2009; 27: 412-418
12. Liu WM, Gravett AM, Dalgleish AG. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int J Cancer 2011; 128: 1471-1480
13. Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/ FasL signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 85-101
14. Leon-Bollotte L, Subramaniam S, Cauvard O, et al. S-nitrosylation of the deaThreceptor fas promotes fas ligand-mediated apoptosis in cancer cells. Gastroenterology 2011; 140: 2009-2018
15. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005; 208: 126-140. (Pubitemid 41746389
16. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma:implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-2143. (Pubitemid 40516580
17. Shaulian E. AP-1-The Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal 2010; 22: 894-899
18. Zhang X, Zhang L, Yang H, et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67: 9425-9434. (Pubitemid 47535933
19. Mathews V, George B, Lakshmi K M, et al. Single-Agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions wiThminimal toxicity. Blood 2006; 107: 2627-2632
20. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-1078. (Pubitemid 351871736
21. EfferThT, Li PC, Konkimalla VS, et al. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007 ; 13: 353-361. (Pubitemid 47126989